SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has initiated a fully-virtual Probuphine® ...

The FDA’s Opioid Analgesic Risk Evaluation and Mitigation Strategy, approved in September, includes several measures to train health professionals on the use of opioid medications and their risks. The ...

The US Food and Drug Administration (FDA) unveiled a new strategy today that will be added to its broader efforts in addressing the current opioid crisis. The agency has approved the final Opioid ...

The growing problem of misuse and abuse of extended-release and long-acting (ER/LA) opioid medications has resulted in a serious public health crisis of addiction, overdose, and death. In 2009, there ...

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily. Mary Williams, a 42-year-old receptionist and mother of three, has a complicated ...

The FDA is requesting public comments on a possible change to the Opioid Analgesic Risk Evaluation and Mitigation Strategy requiring opioid analgesics (OA) used in an outpatient setting to be ...

The main solution to the nation's opioid abuse epidemic is for pharma companies to devise educational programs for physicians on the dangers of overuse, misuse, and abuse of these widely used ...

Please provide your email address to receive an email when new articles are posted on . The FDA can require a safety program called a Risk Evaluation and Mitigation Strategy, or REMS, for a medication ...

ORLANDO -- Opioid overdoses fell after the FDA implemented a class-wide Risk Evaluation and Mitigation Strategy (REMS) for extended release/long-acting (ER/LA) opioids, but deaths did not, researchers ...